Optimal and worst testing strategies for COVID-19

1

35

2	
3	Onishi Tatsuki ^{a,b,c} , Honda Naoki ^{d,e,f} †, Yasunobu Igarashi ^{g,h} *
4	
5	^a Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University,
6	Yoshidakonoecho, Sakyo, Kyoto, Japan
7	^b Department of Anesthesiology and Pain Clinic, Juntendo University Shizuoka Hospital, Izunokuni,
8	Shizuoka, Japan
9	° Department of Anaesthesiology, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida, Tokyo, Japan
10	^d Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University,
11	Higashihiroshima, Hiroshima, Japan
12	e Theoretical Biology Research Group, Exploratory Research Center on Life and Living Systems
13	(ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan
14	^f Laboratory of Theoretical Biology, Graduate School of Biostudies, Kyoto University, Yoshidakonoecho,
15	Sakyo, Kyoto, Japan
16	^g E2D3.org, izumi-cho, Kokubunji, Tokyo, Japan
17	^h Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of
18	Technology, Nagoya, Aichi, Japan
19	
20	* Corresponding author
21	Yasunobu Igarashi
22	Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of
23	Technology
24	Gokiso-cho, Showa-ku, Nagoya, Aichi, 466-8555 Japan
25	Tel.: +81-52-735-5334
26	E-mail: yasunobu.igarashi@gmail.com
27	
28	† Co-corresponding author
29	Honda Naoki
30	Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University,
31	1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima, 739-8511 Japan
32	Tel.: +81-82-424-7336
33	E-mail: nhonda@hiroshima-u.ac.jp
34	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 Abstract

37 Background

During the last three years of fighting COVID-19, governments have been seeking optimal solutions to minimize the negative impacts on societies. They actively used mathematical models such as the susceptible, infectious, exposed, recovered, and dead (SEIRD) model to predict the spread of infection. However, in the end, all governments had difficulty figuring out how to adopt testing strategies.

42

43 Methods

In this study, we developed a testing-SEIRD model, which incorporates testing strategy and testing characteristics. In this model, people who are tested positive are admitted to the hospital within the capacity and medical resources. Through simulations, we examined the infection spread depending on the balance between follow-up testing and mass testing, which test people closely contacted with infected persons and people with symptoms, respectively.

49

50 *Results*

51 We showed that there are optimal and worst combinations of the follow-up and mass testing. These 52 strategies are subject to total resources and cost ratio of testing costs. We also found that these combinations 53 provide an all-or-nothing response for whether the spread of infection expands or extinguishes.

54

55 *Conclusions*

56 While this model alerts us to the existence of a worst testing strategy, it also reveals that an optimal testing

strategy can lead to infection containment. Therefore, the testing-SEIRD model is useful in making decisions
 on testing strategies for the emerging infectious disease outbreaks.

60 Introduction

Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China as global healthcare concern [1,2]. Due to 61 62 its high transmission ability via aerosol, and to lack of a specific treatment in the early stage of the COVID-63 19 Alpha variant pandemic, 5.5 million people have been infected, and 350,000 people have died by April 64 2020 [3]. Medical resource in hospitals is primarily consumed by treatments for COVID-19 patients [1,2]. 65 As of April 2020, approximately 10% of hospital beds, or 10-20% of ICU beds are occupied with COVID-19 66 care [3-5]. Moreover, from May 2020, the COVID-19 Beta variant emerged. Every time a new variant of 67 concern (VOC) emerges, such as the Beta, Gamma, Delta and Omicron variant, society requires an update of 68 knowledge about VOC [6–8].

69 To minimize the number of deaths, society should be aware of the advantages and disadvantages of 70 testing for COVID-19 [9]. From a perspective of individuals, testing has advantages so that asymptomatic 71 infected individuals can be detected and prepared for symptomatic treatment, whereas from a perspective of 72 society, testing prevents secondary infections, expecting the reduction of the number of deaths [10–12]. On 73 the other hand, testing has disadvantages especially at the initial pandemic stage as seen in the Alpha variant 74 pandemic in April 2020, in which no specific treatment was established and testing characteristics, i.e., 75 sensitivity and specificity, are unknown. From a perspective of individuals, the result of testing does not 76 change medical care because of no specific treatment, whereas from a perspective of society, testing is done 77 aimlessly and whether testing results should be trusted was uncertain, resulting in waste of medical and 78 human resources. Therefore, in every early stage of every newly emerging VOC, policymakers should 79 decide the volume of testing with knowledge of the testing characteristics.

80 There was a controversy about the testing policies to minimize the number of deaths in the early 81 stage of the COVID-19 Alpha variant pandemic [7,10,11,13,15–20]. That controversy was between two 82 extreme policies to balance the medical supply and demand: "mass-testing policy" and "no-testing policy" 83 [21]. The mass-testing policy claims that all people must be tested for public health, regardless of the 84 symptoms [22–24]. The mass-testing policy assumes that testing and hospitalization of asymptomatic patient 85 is important to reduce the total number of deaths even in the absence of the specific treatment. Contrary to 86 the mass-testing policy, no-testing policy claims that testing should be limited to symptomatic patient [21]. 87 The no-testing policy assumes that asymptomatic patient cannot expect a benefit from mass-testing in the 88 absence of a specific treatment. Although there is discordance in these two policies with different 89 assumptions, these two policies agree with testing on people with symptoms. They disagree on the extent of 90 the asymptomatic population tested.

What is the most practical testing policy to minimize the number of deaths? The testing strategies for people without symptoms have two options: follow-up testing-dominant strategy that follows and tests the exposed population and mass-testing-dominant strategy that randomly tests the infected population. There remains a problem that it is uncertain to what extent follow-up testing and mass-testing for asymptomatic

populations will affect the number of deaths and lead to the optimal and the worst outcomes especially in
 early stage of emerging VOC in future [7,10,11,13,15–20].

97 In this paper, we developed a testing-SEIRD model, aiming to evaluate the testing strategy with a 98 mixture of follow-up and mass-testing in terms of minimization of the number of deaths in the early stage of 99 the newly emerging VOC. The testing-SEIRD model took account for testing characteristics, testing 100 strategies, hospitalized subpopulation, and the amount of medical resources [25]. Using this model, we 101 examined the worst and optimal testing strategy in the condition that medical resources are both infinite and 102 finite. We then found that the optimal testing strategy largely depends on the cost ratio of mass-testing and 103 follow-up testing. Thus, this study sheds light on how to minimize the number of deaths in the absence of 104 specific treatment in the early stages of pandemic.

106 **Model**

To examine the effect of testing on the infection population dynamics, we developed a new model by introducing a hospitalised subpopulation, testing strategy, and testing characteristics into the classical SEIRD model. In general, the SEIRD model is described by the subpopulation dynamics of susceptible, exposed, infectious, recovered, and dead people (Fig. 1A) as:

111
$$\frac{dS}{dt} = -\frac{bIS}{N},$$
 (2.1)

112
$$\frac{dE}{dt} = \frac{bIS}{N} - gE, \qquad (2.2)$$

113
$$\frac{dI}{dt} = gE - (r+d)I, \qquad (2.3)$$

$$\frac{dR}{dt} = rI,$$
(2.4)

115
$$\frac{dD}{dt} = dI,$$
 (2.5)

where *S*, *E*, *I*, *R*, and *D* indicate the populations of susceptible, exposed, infectious, recovered, and dead people, respectively. *N* indicates the total population, that is, N=S+E+I+R. *b* indicates the exposure rate, which reflects the level of social activity; *g*, *r*, and *d* indicate the transition rates among the subpopulations. For this model, it is assumed that the recovered populations acquire permanent immunity, indicating that they will never be infected.

Regarding the testing-SEIRD model, we incorporated the testing characteristics and testing strategy
into the classical SEIRD model by dividing the population into outside and inside of the hospitals (Fig. 1B).
The dynamics of the population outside the hospitals are described by:

124
$$\frac{dS_o}{dt} = -\frac{bI_oS_o}{N_o} + uE_o - aS_h, \qquad (2.6)$$

125
$$\frac{dE_o}{dt} = -\frac{bI_oS_o}{N_o} - (u+g)E_o - f(1-Sp)E_oH(C-N_h), \qquad (2.7)$$

126
$$\frac{dI_o}{dt} = gE_o - (r_o + d_o)I_o - mSeI_oH(C - N_h),$$
(2.8)

127
$$\frac{dR_o}{dt} = r_o I_o, \tag{2.9}$$

$$\frac{dD_o}{dt} = d_o I_o, \tag{2.10}$$

129 and those inside hospitals were described by:

130
$$\frac{dS_h}{dt} = -\frac{bI_h S_h}{N_h} + uE_h + aS_h, \qquad (2.11)$$

131
$$\frac{dE_h}{dt} = \frac{bI_h S_h}{N_h} - (u+g)E_h + f(1-Sp)E_oH(C-N_h), \qquad (2.12)$$

132
$$\frac{dI_h}{dt} = gE_h - (r_h + d_h)I_h + mSeI_oH(C - N_h), \qquad (2.13)$$

$$\frac{dR_h}{dt} = r_h I_h,\tag{2.14}$$

$$\frac{dD_h}{dt} = d_h I_h, \tag{2.15}$$

135 where X_{a} and X_{b} indicate each population outside and inside the hospitals ($X \in \{S, E, I, R, D, N\}$); N_{a} and N_{b} indicate the total populations outside and inside hospitals, respectively (i.e., $N_e = S_e + E_e + I_e + R_e$ and 136 $N_h = S_h + E_h + I_h$; a indicates the rate of discharge of S_h from hospital to the outside; u and g indicate the non-137 138 infection and infection rates, respectively; C indicates the capacity of hospitals. We assumed that these 139 parameters are determined by the nature of the disease; thus, they are independent of inside and outside 140 hospitals. r_j and d_j ($j \in \{o, h\}$) indicate the recovery and death rates from infection, respectively, where $r_i < r_h$, 141 and $d_k \leq d_k$; f and m indicate the rates of follow-up and mass-testing, corresponding to the extent to which 142 health centers follow exposed populations and take-up infected populations having symptoms, respectively; 143 Sp and Se indicate specificity and sensitivity, respectively, as testing characteristics. The model assumed that 144 I contains a fixed proportion of symptomatic and asymptomatic individuals, and that symptomatic infected 145 individuals receive mass-testing. The hospitalization capacity was introduced by the sigmoid function H(x) = $1/(1+\exp(x))$. The parameter values and initial conditions are listed in Table 1 and discussed in the Materials 146 147 and Methods section.

148

149 **Results**

150 We first examine the basic behavior of the testing-SEIRD model by simulation as shown in Fig. 2. Similar to 151 the classical SEIRD model, infection largely expanded, and the infectious population (I_b and I_c) transiently 152 increased in response to the occurrence of infectious people. Susceptible populations (S_h and S_o) gradually 153 decreased and shifted into recovered populations (R_{h} and R_{o}) through the exposed (E_{h} and E_{o}) and infectious 154 (I_a and I_a) states. During this process, the number of dead cells increases gradually as shown in Fig. 2A. The 155 hospitalized population increase, plateau at the capacity of hospitalizations within the period of infection 156 overshoot, and decrease by the hospital discharge (Fig. 2B). The outside population decrease by 157 hospitalizations through testing and switch to a constant decrease, whereas the hospitalized population 158 reaches its capacity and increases by the hospital discharge (Fig. 2B). Moreover, the outside and hospitalized 159 populations are divided into five types of populations (susceptible, exposed, infectious, recovered, and dead) 160 (Fig. 2C and D). Daily reports of positive tests and deaths transiently increase with different peak timings, 161 and the peak of positive tests precedes that of deaths (Fig. 2E). Reproduction numbers (see Materials and 162 Methods) outside hospitals RN_{e} switch from greater than one to less than one around the peak timing of 163 infectious populations outside (Fig. 2F). On the contrary, reproduction numbers inside hospitals RN_{*} are less 164 than one. This indicates that the infectious population in hospitals increases owing to supply from the 165 outside; however, it is not because of the infectious spread in hospitals. The testing-SEIRD model 166 recapitulates basic infection dynamics of the total population as observed in the classical SEIRD model (Fig. 2A), and enables us to examine the effect of the testing strategy and testing characteristics with different 167 168 populations inside and outside hospitals.

169 To investigate the impact of hospitalization capacity on infection dynamics, such as daily reports of 170 positive tests, hospitalizations, and deaths, we simulate the testing-SEIRD model with various capacities (Fig. 171 3A to C). We observe that as the capacity increases, the maximum positive tests, maximum hospitalizations, 172 and cumulative deaths linearly decrease, increase, and decrease, respectively, and they all plateau at 173 approximately 30% capacity (Fig. 3D to F). We have also examined their peak timings and have observe that 174 they change nonlinearly, with certain time window ranges (Fig. 3G–I). These results suggest that the change 175 in capacity has a large effect on the level of spread of the disease; nonetheless, it has a small effect on timing. 176 To illustrate the impact of the testing strategy on infectious outcomes, we examined the cumulative

deaths, maximum number of positive tests and hospitalizations, varying follow-up and mass-testing rates.
The infectious spread shows an all-or-none response depending on the testing strategy (red and blue regions
in Fig. 4). Sensitivity analyses confirmed that such a profile was robustly maintained independent of the
model parameters (Fig. S1 and S2).

181 The number of cumulative deaths is almost constant with a small amount of both the follow-up and 182 mass-testing (red region in upper panel of Fig. 4A); nonetheless, the combination of follow-up and mass-183 testing cooperatively suppresses the infectious spread (blue region in the upper panel of Fig. 4A). We also 184 realize that the maximum number of hospitalizations is immediately saturated by either the follow-up or

185 mass-testing because of the limited hospitalization capacity (upper panel in Fig. 4B). The maximum number 186 of positive tests increases more efficiently with the follow-up testing rate compared to the mass-testing rate 187 (upper panel in Fig. 4C).

Subsequently, realistic scenarios were considered by adapting the limited resource L. Practically, we cannot freely control the follow-up and mass-testing rates because of the limited medical resource for both the follow-up and mass-testing. Thus, it is necessary to determine the amount of resource allocated to the follow-up and mass-testing. Here, we consider all the possible decisions subject to the limited resource L as:

192

$$L = c_f f + c_m m, \tag{3.1}$$

193 where c_r and c_{**} indicate the costs for follow-up and mass-testing, respectively; *f* and *m* are reflected by the 194 decisions on how much follow-up and mass-testing are conducted. Considering different *L*, c_r , and c_{**} , based 195 on the disease, economic and technological situations of each country, we depicted three lines. The three 196 colored lines in the heat maps correspond to a cost ratio of 1:10, 1:5, and 1:1 for follow-up and mass-testing, 197 respectively (Fig. 4). Given the total amount of resources, we can choose the optimal testing strategy on the 198 line represented by the equation (3.1). We observe that the worst decisions (i.e., the choice of *f* and *m*) 199 drastically varied depending on the situation (lower panels of Fig. 4).

200 Regarding the high resource and low ratio of the cost of follow-up testing to that of the mass-testing 201 cost, the number of cumulative deaths abruptly increases as the resource fraction of mass-testing exceeds 202 90% (green line in Fig. 4A). This indicates that the mass-testing dominant testing is the worst strategy for 203 minimizing the cumulative deaths. On the other hand, considering low resource and high ratio of follow-up 204 cost to mass-testing cost, the number of cumulative deaths abruptly decreases at the resource fraction of 20% 205 to 30 % (blue line in Fig. 4A) assigned to mass-testing. Contrary to the previous case, this result suggests 206 that follow-up-dominant testing is the worst strategy. Regarding the intermediate situation between the two 207 cases above, the simulation showed a U-shape with the resource fraction assigned to mass-testing ranging 208 from approximately 10 to 80 % (orange line in Fig. 4A). These results clearly suggested that both follow-up 209 and mass-dominant testing are strategies to avoid, whereas the optimal strategy is a combination of the 210 follow-up and mass-testing. The choice of f and m also changed in the profiles of maximum hospitalizations 211 and positive reports (Fig. 4B and C). Taken together, the optimal strategy for each country/region should be 212 sought with the resource considered.

213 Moreover, we examined how the three variables (i.e., the number of cumulative deaths, 214 hospitalizations, and positive tests) are affected by the testing characteristics (i.e., sensitivity and specificity). 215 We conducted sensitivity analyses for Se and Sp with values from zero to four with 0.01 increments. We 216 obtained almost the same heatmaps in the sensitivity-specificity space although the heatmaps were inverted 217 along the x-axis (Fig. 5). The equations (2.7, 2.8, 2.12, and 2.13) reveal that sensitivity and one-specificity 218 essentially play the same roles in the follow-up and mass-testing. The sensitivity and specificity of the test 219 are not modifiable, whereas the testing strategy can be arbitrary. If the sensitivity is low, an increase in the 220 mass-testing rate can lead to the same infectious result with high sensitivity. On the contrary, if the 221 specificity is low, a decrease in the follow-up testing rate can lead to the same infectious result with high

specificity. Therefore, we must manage the optimal testing strategy based on the unmodifiable testing sensitivity and specificity.

224 We have investigated how the infection is expanded based on the testing strategy. However, this is 225 the point of view of a perfect observer who knows the exact time course of the latent populations. Practically, 226 we are unable to know all the model variables, such as exposed and infectious populations inside and outside 227 hospitals; nonetheless, we can merely monitor positive reports by follow-up and mass-testing. In this study, 228 we verify whether these two kinds of positive reports reflect the latent infectious population, which is the 229 most resource-consuming and challenging social issue. Using regression analysis (see Materials and 230 Methods), we demonstrate that latent infectious populations can be predicted from daily positive reports of 231 follow-up and mass-testing (Fig. 6A to C). These results suggest that the infectious population is not simply 232 proportional to the sum of positive reports of follow-up and mass-testing; nevertheless, they are proportional 233 to their weighted sum (Fig. 6D). There are cases in which either weights can be negative, depending on the 234 model parameters. We found that the weight for positive reports of follow-up testing was negative with high 235 positive predictive values. This is because the negative weight of P_{t} acts in a repressive manner to estimate 236 the latent number of infectious people, reflecting a low positive predictive value (Fig. 6D).

238 **Discussion**

239 We develop a testing-SEIRD model to consider two discrete populations inside and outside hospitals, impact 240 of testing strategy (follow-up testing [f], and mass-testing [m]), and testing characteristics (sensitivity [Se]and specificity [Sp]) on three variables (i.e., the number of maximum positive tests, maximum 241 242 hospitalizations, and cumulative deaths (Fig. 1)). By simulating the model with parameters, which describe 243 the early stage of the COVID-19 Alpha variant pandemic, we demonstrate that the optimal and the worst 244 testing strategies are subject to limited medical resource (Fig. 4). In addition, we highlight the possibility that 245 the infectious population can be predicted by a weighted sum of positive reports from follow-up and mass 246 testing (Fig. 6).

247

248 *Comparison with previous models*

249 There are several models of infectious dynamics, such as SIR [26] SEIRD models, and their 250 alternatives, which have been widely used for policy making through model simulation [1,27–34]. However, 251 some of the previous models do not include the hospital compartment, [28,33,35–37] and other models, even 252 with hospital compartments, do not consider the testing strategy and testing characteristics [30,38]. They 253 cannot address how the testing strategy and testing characteristics affect the number of deaths. Consequently, 254 we develop the testing-SEIRD model by introducing new factors: the hospital compartment, testing strategy, 255 testing characteristics, and medical resource to the previous SEIRD model (Fig. 2-4). The testing-SEIRD 256 model generalizes the classical SEIRD model, and it can be equivalent to the classical SEIRD model if the 257 testing strategy is removed (*f*=0, *m*=0).

258

259 Model prediction

260 Our model has three advantages. First, the testing-SEIRD model provides the best testing strategy 261 for situations. The model provides heatmaps of the number of the three variables in the space of the testing 262 strategy (Fig. 4). These heatmaps indicate the best direction as shown in the blue region in Fig. 4. This 263 corresponds to the settling of infections using the shortest path. Second, the testing-SEIRD model can predict 264 the optimal and worst strategies, considering the limited medical resource and ratios for the testing costs (Fig. 265 4). Because the total medical resource and testing costs depend on countries, our model offers the best 266 testing strategy unique to each country. Third, the testing-SEIRD model demonstrates that the latent number 267 of infectious populations can be predicted from daily positive reports of the follow-up and mass-testing (Fig. 268 6).

269

270 Validity of model components

Here, we discuss the validity of the model components, which previous models do not have. First, we focus on the transition from E_{\circ} to E_{\circ} (Fig. 1). We assume that the hospitalization of the exposed population is induced by the follow-up testing. Populations that are just exposed before developing symptoms do not take

274the tests themselves. They test only when urged by the follow-up. Second, related to the transition from I_a to 275 I_b, we assume that the hospitalizations of the infectious population are induced by the mass-testing, which is 276 defined as a person with symptoms. Considering our model, we address the rate of mass-testing as a 277 modifiable parameter because the rate depends on the volume of the tests, such as polymerase chain reaction 278 (PCR) and the degree of social penalty if it is positive. Third, we consider the transition from E_{\bullet} to S_{\bullet} and E_{\bullet} 279 to S_b. Regarding our model, all the exposed populations are not necessarily infected and some return 280 susceptible compared to the previous models which assume that all the exposed populations are destined to 281 be infected [28,30,32,33,35–41]. Consistent with our model, it is well known that some exposed populations 282 return to susceptible populations without developing symptoms. Finally, our model is not specific to the 283 Alpha variant, but is applicable to other VOCs, because the assumptions mentioned above about exposure, 284 infection and hospitalization processes are common in VOCs [8]. Taken together, new components 285 introduced into the testing-SEIRD model not only are consistent with the previous simulation model, but also 286 reflect and incorporate a practical point of view.

287

288 Validity of model parameters

289 We used parameters from the previous reports before the Beta variant appeared in South Africa in 290 May 2020 [8] (Table 1) because the earlier reports are homogeneous Alpha variant data. After May 291 2020, the reports are an inhomogeneous mixture of multiple variants. We set sensitivity and specificity of 292 testing to 0.7 and 0.7 accordingly and the results were robustly guaranteed by a sensitivity analysis (Fig. 4). 293 As the incubation and infectious periods remain roughly stable in the VOCs, while the number of 294 reproductions and mortality rates vary among variants [8,12,14]. The number of reproductions, reinfection 295 [42] effects were robustly guaranteed by a sensitivity analysis of b and u (Fig. S1). Mortality was taken into 296 account in the model with d_{a} and d_{b} and these values are sensitivity analyzed (Fig. S2). a or the rate of 297 discharge from S_{h} was robustly guaranteed by a sensitivity analysis (Fig. S3). Although these values are 298 based on the COVID-19 Alpha variant, our sensitivity analysis indicates that the testing-SEIRD robustly 299 generated the optimal and worst testing strategy for other VOCs having different parameters.

300

301 Future studies

302 Considering the future perspectives of our model, first, our testing-SEIRD model simulates only a 303 single peak time course of infection. However, we observed multiple peaks of COVID-19 infection in many 304 countries [43]. To incorporate the multiple peaked dynamics, we must introduce the socio-psychological 305 effects caused by policies such as lockdown and social distancing. Second, our model assumes that all the 306 populations are homogeneous and do not address stratification based on attributes such as gender, age, social 307 activities, and comorbidities [44,45]. A future study should consider this perspective. Finally, our model 308 does not include the effects of vaccination. We are currently fighting the spread of COVID-19 using 309 messenger RNA (mRNA) vaccines. It seems we are getting successful results; however, we do not know the

- 310 duration of the effect of the vaccinations or acquired immunity and its effectiveness against VOCs [43,46,47].
- 311 Therefore, the tag-of-war model between vaccines and virus evolution remains elusive.

313 Materials and Methods

314 Parameter set

315 The parameters and initial conditions of the simulation are listed in Table 1A. We used parameters based on the studies of the COVID-19 Alpha variant. The total population N was set to 1,000,000 according 316 317 to the United Nations Statistical Papers: The World's Cities in 2018, which mentioned that one in five people worldwide lives in a city with more than one million inhabitants and the median value of inhabitants is 318 319 between 500,000 and one million [48]. Sensitivity Se and specificity Sp were both set to 0.7, which 320 correspond to those of the PCR for detecting COVID-19 (Table 1B) [28,39,49–51]. The values of b, g, r_h, r_o , 321 and d_h are based on previous reports (Table 1C) [3,29–34,36–38,42]. The sum of u and g is the inverse of the 322 incubation period during the exposed state, which is reported to be five days (Table 1C) [31-33,41,50]. The 323 sum of r and d is the inverse of the infectious period during the infectious state, which is reported to be ten 324 days (Table 1D) [31,32,35,50].

325

326 **Definitions of reproduction numbers**

327 Considering Fig. 2, we computed the time courses of reproduction numbers inside and outside 328 hospitals: RN_h and RN_o .

$$RN_h = \frac{1}{r_h + d_h} \cdot \frac{bS_h}{S_h + E_h + I_h} \cdot \frac{g}{u + g},\tag{5.1}$$

330

$$RN_{o} = \frac{1}{r_{o} + d_{o}} \cdot \frac{bS_{o}}{S_{o} + E_{o} + I_{o} + R_{o} + R_{h}} \cdot \frac{g}{u + g}.$$
(5.2)

Here, the first, second, and third factors in these equations indicate the average infectious period, infection rate, and probability that the exposed state transits to the infectious state, respectively. The reproduction number in the classical SEIRD model is defined in previous studies [1,27–34] as:

334
$$RN = \frac{1}{r+d} \cdot \frac{bS}{S+E+I+R}.$$
 (5.3)

336 Acknowledgments

We thank Tomohiko Takada M.D. (Ph.D.) and Yoshika Onishi M.D. (Ph.D.) for providing the basic concept of clinical NNT. We thank Yoshiaki Yamagishi M.D. (Ph.D.), Tomokazu Doi M.D. (Ph.D.), and Tatsuyoshi Ikenoue M.D. (Ph.D.) for polishing early manuscript. We also thank Prof. Hiroshi Nishiura for providing the fundamental

340 knowledge of infectious disease modelling by organising a summer boot camp in 2014.

341

342 Funding

This study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for Transformative Research Areas (B) [grant number 21H05170], a Grant-in-Aid for Scientific Research (B) (21H03541 to H.N.) from the Japan Society for the Promotion of Science (JSPS).

347

348 Ethics

- 349 Any human or animal subjects are not involved in this manuscript.
- 350

351 Data Availability

- 352 All relevant data are within the study and its supporting information files.
- 353

354 Code Availability

All codes to reproduce the results of this study are hosted in Github at https://github.com/bougtoir/testing-SEIRD.

357 Author Contributions

O.T. and Y.I. conceived of the initial ideas. O.T. developed and implemented the method, processed, and analysed
the data, and wrote the initial draft of the manuscript. H.N. edited the initial draft of the manuscript and reviewed
the method. Y.I. supervised the project. All authors contributed to the final writing of the manuscript.

361

362 Competing Interests

363 The authors declare no competing interests.


365 **References**

- Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. 2020 COVID-19 infection: Origin,
 transmission, and characteristics of human coronaviruses. *Journal of Advanced Research* 24, 91–98. (doi:10.1016/j.jare.2020.03.005)
- Kolifarhood G, Aghaali M, Saadati HM, Taherpour N, Rahimi S, Izadi N, Saeed S, Nazari
 H. 2020 Epidemiological and Clinical Aspects of COVID-19; a Narrative Review. *Archives ofAcademic EmergencyMedicine* 8, 41.
- Johns Hopkins Coronavirus Resource Center. In press. COVID-19 Map Johns Hopkins
 Coronavirus Resource Center. See https://coronavirus.jhu.edu/map.html (accessed on 21
 May 2020).
- Our world in Data. In press. GitHub owid/covid-19-data: Data on COVID-19
 (coronavirus) cases, deaths, hospitalizations, tests All countries Updated daily by Our
 World in Data. See https://github.com/owid/covid-19-data (accessed on 31 March 2022).
- 3795.Centers for Disease Control and Prevention. 2021 COVID Data Tracker, Centers for380Disease Control and Prevention. See https://covid.cdc.gov/covid-data-381tracker/#datatracker-home (accessed on 31 March 2022).
- 3826.World Health Organization. In press. Coronavirus disease 2019 (COVID-19) Situation383Report 46.
- World Health Organization. 2020 Laboratory testing strategy recommendations for
 COVID-19. See https://apps.who.int/iris/bitstream/handle/10665/331509/WHO COVID-19-lab_testing-2020.1-eng.pdf.
- 387 8. World Health Organization (WHO). In press. tracking-SARS-CoV-2-variants. See
 388 https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
- 3899.Joebges S, Biller-Andorno N. 2020 Ethics guidelines on COVID-19 triage An emerging390international consensus. Critical Care 24, 1–5. (doi:10.1186/s13054-020-02927-1)
- 39110.Yan Bai, MD Lingsheng Yao, MD TaoWei, MD Fei Tian, MD Dong-Yan Jin, PhD Lijuan392Chen, PhD MeiyunWang, MD P. 2020 Letters Presumed Asymptomatic Carrier393Transmission of COVID-19. (doi:10.1001/jama.2020.2565)
- 39411.Al-Sadeq DW, Nasrallah GK. 2020 The incidence of the novel coronavirus SARS-CoV-2395among asymptomatic patients: A systematic review. International Journal of Infectious396Diseases 98, 372–380. (doi:10.1016/j.ijid.2020.06.098)
- 39712.Mallett S et al. 2020 At what times during infection is SARS- CoV-2 detectable and no398longer detectable using RT-PCR-based tests? A systematic review of individual399participant data. BMC Med 18, 1–17. (doi:doi:10.1186/s12916-020-01810-8)
- 400 13. Yukari C. Manabe M, Joshua S. Sharfstein M, Katrina Armstrong M. 2020 The Need for

401		More and Better Testing for COVID-19. (doi:10.1001/jama.2020.21694)
401	14.	Rhee C, Kanjilal S, Baker M, Klompas M. 2021 Duration of Severe Acute Respiratory
402	14.	Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue
403 404		Isolation? <i>Clinical Infectious Diseases</i> 72 , 1467–1474. (doi:10.1093/cid/ciaa1249)
404	15.	Wilson E, Donovan C v, Campbell M. 2020 Multiple COVID-19 Clusters on a University
403 406	15.	Campus —. <i>MMWR Morb Mortal Wkly Rep</i> 69 , 1416–1418.
400 407	16.	Id VB, Mallein B. 2021 Group testing as a strategy for COVID-19 epidemiological
407 408	10.	monitoring and community surveillance. <i>PLoS Computational Biology</i> 17 , 1–25.
408 409		(doi:10.1371/journal.pcbi.1008726)
409 410	17.	Organisation for Economic Cooperation and Development. 2020 Testing for COVID-19:
	17.	
411		
412		ilibrary.org/view/?ref=129_129658-l62d7lr66u&title=Testing-for-COVID-19-A-way-to-lift-confinement-restrictions.
413 414	10	
414 415	18.	Signorini SG, Brugnoni D. 2021 Less is more: an ecological and economic point of view on appropriate use of lab testing for COVID patients. <i>Bioanalysis</i> , 7–9. (doi:10.4155/bio-
415 416		2021-0064)
	10	
417 418	19.	Centers for Disease Control and Prevention. 2020 Overview of testing for SARS-CoV-2 (COVID-19). See https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-
419 420	20	overview.html. Accessed 29 August 2020.
420 421	20.	Id DRB, Bish EK, El-hajj H, Aprahamian H. 2021 A robust pooled testing approach to expand COVID-19 screening capacity. <i>PLoS ONE</i> , 1–15.
421		expand COVID-19 screening capacity. <i>PLoS ONE</i> , 1–15. (doi:10.1371/journal.pone.0246285)
422	21.	Japanese society of pediatrics. In press. Thought on COVID-19 testing. See
423 424	21.	
424 425		http://www.jpeds.or.jp/modules/activity/index.php?content_id=329 (accessed on 21 May 2020).
423 426	22.	
420 427	22.	World Health Organization. In press. WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 March 2020. See https://www.who.int/director-
427		general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-
428 429		on-covid-1916-march-2020 (accessed on 21 May 2020).
429	23.	Godlee F. 2020 The burning building. <i>The BM</i> /368 , 2020. (doi:10.1136/bmj.m1101)
430 431	23. 24.	Peto J. 2020 Covid-19 mass testing facilities could end the epidemic rapidly. <i>The BM</i> / 368 ,
431	24.	110110. (doi:10.1136/bmj.m1163)
432 433	25.	World Health Organization. 2021 COVID-19: Laboratory and diagnosis.
433 434	25. 26.	Phelan. 2018 Mathematical models to characterize early epidemic growth: A Review
434 435	20.	Gerardo. <i>Physiol Behav</i> 176 , 139–148. (doi:10.1016/j.plrev.2016.07.005.Mathematical)
435 436	27.	Roguski KM <i>et al.</i> 2019 Estimates of global seasonal influenza-associated respiratory
	21.	
437		mortality: a modelling study. The Lancet 391 , 1285-1300. (doi:10.1016/S0140-

438		6736(17)33293-2)
439	28.	Fang Y, Nie Y, Penny M. 2020 Transmission dynamics of the COVID-19 outbreak and
440		effectiveness of government interventions: A data-driven analysis. J Med Virol
441		(doi:10.1002/jmv.25750)
442	29.	Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. 2020 An updated estimation of the risk
443		of transmission of the novel coronavirus (2019-nCov). Infect Dis Model 5, 248-255.
444		(doi:10.1016/j.idm.2020.02.001)
445	30.	Kucharski AJ et al. 2020 Early dynamics of transmission and control of COVID-19: a
446		mathematical modelling study. The Lancet Infectious Diseases 20, 553–558.
447		(doi:10.1016/S1473-3099(20)30144-4)
448	31.	Backer J, Klinkenberg D, Wallinga J. 2020 The incubation period of 2019-nCoV infections
449		among travellers from Wuhan, China. <i>Eurosurveillance</i> , 1–6.
450		(doi:10.1101/2020.01.27.20018986)
451	32.	Bi Q et al. 2020 Epidemiology and transmission of COVID-19 in 391 cases and 1286 of
452		their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet
453		Infectious Diseases 20, 911–919. (doi:10.1016/S1473-3099(20)30287-5)
454	33.	Kuniya T. 2020 Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. J
455		<i>Clin Med</i> 9 . (doi:10.3390/jcm9030789)
456	34.	Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B,
457		Kinoshita R, Nishiura H. 2020 Incubation period and other epidemiological characteristics
458		of 2019 novel coronavirus infections with right truncation: A statistical analysis of publicly
459		available case data. <i>Journal of Clinical Medicine</i> 9 , 538.
460		(doi:10.1101/2020.01.26.20018754)
461	35.	Joseph TW, Leung K, Leung GM. 2020 Nowcasting and forecasting the potential domestic
462		and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
463		modelling study. The Lancet 395, 689-697. (doi:10.1016/S0140-6736(20)30260-9)
464	36.	Iwata K, Miyakoshi C. 2020 A Simulation on Potential Secondary Spread of Novel
465		Coronavirus in an Exported Country Using a Stochastic Epidemic SEIR Model. Journal of
466		<i>Clinical Medicine</i> 9 , 944. (doi:10.3390/jcm9040944)
467	37.	Sun H, Qiu Y, Yan H, Huang Y, Zhu Y, Gu J, Chen S. 2021 Tracking Reproductivity of
468		COVID-19 Epidemic in China with Varying Coefficient SIR Model. Journal of Data
469		Science 18, 455-472. (doi:10.6339/jds.202007_18(3).0010)
470	38.	Rocklöv J, Sjödin H, Wilder-Smith A. 2021 COVID-19 outbreak on the diamond princess
471		cruise ship: Estimating the epidemic potential and effectiveness of public health
472		countermeasures. Journal of Travel Medicine 27, 1–7. (doi:10.1093/JTM/TAAA030)
473	39.	Lin L et al. 2020 Artificial Intelligence Distinguishes COVID-19 from Community
474		Acquired Pneumonia on Chest CT. Applied Intelligence 2019, 1–5.


475		(doi:10.1148/radiol.2020200905)							
476	40.	Roda WC, Varughese MB, Han D, Li MY. 2020 Why is it difficult to accurately predict the							
477		COVID-19 epidemic? Infect Dis Model 5, 271–281. (doi:10.1016/j.idm.2020.03.001)							
478	41.	World Health Organization. 2020 China Joint Mission on Coronavirus Disease 2019							
479		(COVID-19). World health organization. 2019 , 16–24. See							
480		https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-							
481		coronavirus-disease-2019-(covid-19) (accessed on 21 May 2020).							
482	42.	Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ,							
483		Dushoff J, Mlisana K, Moultrie H. 2022 Increased risk of SARS-CoV-2 reinfection							
484		associated with emergence of Omicron in South Africa. Science (1979) 376, 1-43.							
485		(doi:10.1126/science.abn4947)							
486	43.	GISAID. In press. GISAID - Initiative. See https://www.gisaid.org/ (accessed on 9 May							
487		2021).							
488	44.	Shahid Z et al. 2020 COVID-19 and Older Adults: What We Know. J Am Geriatr Soc 68,							
489		926–929. (doi:10.1111/jgs.16472)							
490	45.	Thomas DM, Sturdivant R, Dhurandhar N v., Debroy S, Clark N. 2020 A Primer on							
491		COVID-19 Mathematical Models. <i>Obesity</i> 28, 1375–1377. (doi:10.1002/oby.22881)							
492	46.	Sharp TM et al. 2021 Antibody Persistence through 6 Months after the Second Dose of							
493		mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine 384, 2257-2259.							
494		(doi:10.1056/nejmc2023298)							
495	47.	Christian HH, Daniela M, Sophie MG, Kåre M, Steen E. 2020 Assessment of protection							
496		against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark							
497		in 2020: a population-level observational study Christian. The Lancet , 19–21.							
498		(doi:10.1016/ S0140-6736(21)00575-4)							
499	48.	United Nations. 2018 The World's Cities in 2018: Data Booklet.							
500		(doi:10.18356/C93F4DC6-EN)							
501	49.	Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. 2020 Correlation of							
502		Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A							
503		Report of 1014 Cases. Radiology, 200642. (doi:10.1148/radiol.2020200642)							
504	50.	Long C et al. 2020 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?							
505		European Journal of Radiology 126. (doi:10.1016/j.erad.2020.108961)							
506	51.	Lai S et al. 2021 Effect of non-pharmaceutical interventions to contain COVID-19 in							
507		China. Natutre 585, 410-413. (doi:10.1038/s41586-020-2293-x.Effect)							
508									



509

510 Figure 1: Classical SEIRD and testing-SEIRD models


511 (A) Classical SEIRD model: Susceptible population 'S' is exposed by infectious population 'I' at a rate 512 proportional to the fraction of the infectious population. The exposed population 'E' become infectious 'I'. The 513 infected population finally recovers 'R' or become dead 'D'. (B) Testing-SEIRD model: The population is 514 divided into two subpopulations; inside and outside hospitals. The exposed 'Eo' and infectious population 515 outside 'lo' are hospitalised if evaluated as positive by testing. Susceptible population 'Sh' is left from the 516 hospitals. The black lines indicate the transitions of populations, regardless of capacity effect. The blue lines 517 indicate the transitions of the populations, considering the capacity effect. Transitions from both 'Eo' to 'Eh' 518 and 'lo' to 'lh' are determined as hospitalised.



520

521 Figure 2: Changes in components over time in the testing-SEIRD model

Time-courses of (A) populations of all infectious states, irrespective of being inside and outside hospitals; (B)
Populations inside and outside hospitals and dead populations, irrespective of infectious states; (C)
Populations of all infectious states inside hospitals; (D) Populations of all infectious states outside hospitals;
(E) Daily reports of positive tests, hospitalisations, and deaths; (F) Time-courses of reproduction numbers
inside and outside hospitals, as described in Materials and Methods section.



531 Figure 3: Impact of hospitalisations capacity on the three variables

532 Time courses of (A) Daily reports of positive tests; (B) Daily reports of hospitalisations; (C) Daily reports of 533 deaths with varying hospitalisation capacity. C/N indicates the capacity normalised to the total population.

Hospitalisation capacity dependencies of (D) Maximum positive reports; (E) Maximum hospitalisations; (F)


535 Cumulative deaths. Hospitalisation capacity-dependencies of (G) Peaks of daily reports of positive tests; (H)

536 Peaks of hospitalisations; (I) Peaks of daily deaths.

537

530

538



539

540 Figure 4: Infectious spread based on the testing strategy


541 The upper panels represent the number of (A) cumulative deaths, (B) maximum hospitalizations, and (C)

542 maximum daily positive tests depending on the rates of follow-up and mass-testing. The three lines in these 543 heatmaps represent the possible testing strategies subject to different total resource for testing with different

ratios for the testing costs. The middle panels represent the numbers along the three lines in the heatmaps.


545 The lower panels represent semilog-plots of the middle panels. L=500, $c_{r}=1$, $c_{m}=10$ in the green line, L=300,

546 $c_f = 1, c_m = 5$ in the blue line, and $L = 100, c_f = 1, c_m = 1$ in the orange line.



548 Figure 5: Infectious spread based on the testing properties

- 549 Number of (A) Cumulative deaths, (B) Maximum hospitalisations, and (C) Maximum daily positive tests
- 550 based on the sensitivity and specificity of the testing.



551

552 Figure 6: Prediction of infectious population from daily reports of positive tests

553 (A-C) The Green and orange lines indicate the simulated and predicted infectious populations (I_h and I_o) with 554 different testing strategies. The infectious populations are estimated by the linear regression *as* $w_fP_f + w_mP_m$, 555 where w_f and w_m indicate the weights and P_f and P_m indicate the daily positive reports of follow-up and mass-556 testing, namely *f* (*1-Sp*) and *mSe*, respectively. The weights are estimated by the least square method. (D) 557 The estimated weights for P_f and P_m are plotted, considering various combinations of ratios of the follow-up 558 cost to the mass-testing cost (P_f/P_m).


560

А		С							
Variable	Value	Reference	Model	b	g	r _h	ro	dh	do
Sh, Eh, Ih	1	Fang ²⁸	eSEIR	0.9 e-5 to e-6†	0.143	0.056	n/a	n/a	n/a
10	97	Tang ²⁹	n/a	2.1 e-8	0.126	n/a	0.14	1.78 e-5	n/a
S.	999900	Kucharski ³⁰	eSEIR	n/a	0.156	n/a	n/a	n/a	n/a
Eo,Rh,Ro,Dh,	<i>D</i> ∘ 0	Backer ³¹	n/a	n/a	0.143 to 0.33	n/a	n/a	n/a	n/a
		Bi Q ³²	n/a	n/a	n/a	n/a	n/a	n/a	n/a
		Kuniya ³³	SEIR	0.2 e-8†	n/a	n/a	n/a	n/a	n/a
Parameter	r Value	Linton ³⁴	n/a	n/a	0.2	n/a	n/a	n/a	n/a
Se	0.7	- Iwata ³⁶	SEIR	n/a	0.167 to 0.208	0.13 to 0.417	n/a	n/a	n/a
Sp	0.7	Sun ³⁷	vSIR	n/a	n/a	0.1	n/a	n/a	n/a
f	0.05	Rocklöv ³⁸	SEIR	0.4 e-4 or 0.12 e-4†		n/a		n/a	n/a
m	0.01						n/a		
b	1	Roda ⁴⁰	SIR/SEIR	8.68 e-8	0.631	0.1	n/a	n/a	n/a
u	0.04								
g	0.16								
ľh	0.093			D	Reference	Incubation period		Infectious period	
r∘ d⊨	0.096 0.007				Kucharski ³⁰	5.2		2.9	
do do	0.007				Backer ³¹	6.5		n/a	
u.	0.01				Bi Q ³²	4.8		1.5	
_					Wu ³⁵	6.1			
Вм	lode of test	Se	Sp					2.3	
		0.9828, 0.9739,50,	0.000 / 0.0051	_	Rocklöv ³⁸	5		10	
	CT	0.8 to 0.951,0.97252	0.828 to 0.9651		Lin ³⁹	5.2		2.3	
	PCR	0.7128,0.84652	n/a	WH	łO₋China Joint⁴¹	5.5		n/a	

561

562 Table 1: Variables and parameters in reports during the early stage of pandemic

(A) Initial values for variables and parameters and (B) Reported sensitivity and specificity of PCR and CT for detecting COVID-19. Cells expressed as n/a indicate that we cannot find the (C) reported transition parameters with models. Values with † are calculated from the original values for comparison. All the values have dimensions of [one/day]. We cannot find values or models for the cells expressed as n/a. The values with † equal original values divided by the total population involved. (D) Reported incubation period and infectious period. All values have dimensions of [day].




570 Supplementary Figures






- 573 Simulations were performed with different values of *b* and *u*.
- 574



577 Figure S2: Sensitivity analyses of d_0 and d_h on the number of cumulative deaths

- 578 Simulations were performed with different values of d_o , d_h , where (d_o, d_h) of (0.01, 0.007) is a reference
- 579 standard, (0.01, 0.001) means advance in treatment, (0.01, 0.01) means futile treatment, and (0.001, 0.0007)
- 580 means reduction in overall mortality.
- 581



582
 583
 Figure S3: Sensitivity analyses of parameter *a* on the number of cumulative deaths

584 Simulations were performed with different values of parameter *a*.